Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Canadian Federal Court Refuses Permanent Injunction Against JAMP’s Simlandi® (adalimumab) for Infringement of AbbVie’s Humira® Patent

Dec 4, 2023

The Canadian Federal Court has refused AbbVie’s application for a permanent injunction against JAMP for exploitation of Simlandi® until the expiration of AbbVie’s Humira® patent no. 2,904,458.  Despite JAMP conceding it infringed the ‘458 patent, it successfully argued that the injunction should not be granted for public interest reasons.  It argued that: 

  • there was an alternative remedy available (a reasonably royalty paid by JAMP to AbbVie); 
  • Humira® would not benefit from additional sales if Simlandi® was removed from the market as Simlandi® patients would be switched to another biosimilar for which AbbVie is likely receiving a royalty;  
  • the removal of Simlandi® would deprive patients of the only 80 mg/0.8 mL formulation available in Canada; and 
  • if Simlandi® and Yuflyma® (Celltrion) are removed, all Simlandi® patients will have to switch to a biosimilar with a higher injection volume and possibly citrate, which could increase injection site pain for these patients and cause them harm. 

The Court also found that two of AbbVie’s Humira® dosing regimen patents (nos. 2,504,868 and 2,801,917)were invalid for obviousness.